Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
K.JonesK
Consult a healthcare professional if unsure
For in-depth articles and resources, visit onthepen.com
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
Refrain from visiting spas and saunas for at least 3 days post-treatment
US$ 29.82
US$ 27.29
US$ 27.75
US$ 27.88
US$ 26.25
US$ 20.74
US$ 22.82
US$ 21.28
US$ 23.53
US$ 29.86
US$ 23.02
